These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Views of Louisiana pharmacists on drug product selection. Iyriboz Y; Church G J La State Med Soc; 1986 Nov; 138(11):41-5. PubMed ID: 3794682 [No Abstract] [Full Text] [Related]
23. Benefits and liabilities of generic prescribing. Lee AM W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384 [No Abstract] [Full Text] [Related]
29. Pharma's year of trouble and strife. Frantz S Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339 [No Abstract] [Full Text] [Related]
30. LyphoMed sparks worries. Wagner M Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202 [No Abstract] [Full Text] [Related]
31. Bioequivalence studies: a new EMA guideline. Houin G Arzneimittelforschung; 2010; 60(4):169-70. PubMed ID: 20486464 [No Abstract] [Full Text] [Related]
32. Quality drugs and the Saskatchewan formulary. Johnson GE Can J Hosp Pharm; 1975; 28(3):84-6. PubMed ID: 10316621 [No Abstract] [Full Text] [Related]
37. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300 [TBL] [Abstract][Full Text] [Related]
38. QUAD routes out inferior drugs. Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804 [No Abstract] [Full Text] [Related]
39. What's best for the patient? Burkle WS Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359 [No Abstract] [Full Text] [Related]